Merck Canada Inc. researches, develops, manufactures, and markets prescription medicines, vaccines, biologic therapies, and consumer care and animal health products. The company offers various vaccines for the prevention of rare diseases, such as measles and mumps, shingles, and cervical cancer; prescription products in various therapeutic areas, such as cardiovascular disease, respiratory disease, oncology, neuroscience, infectious disease, and women's health; and consumer healthcare products that help to prevent or treat various common conditions, including allergies, sun care, foot care, nasal and cough/cold care, digestive care, and more. It also offers veterinary medicines, including va...
16750 Trans Canada Highway
Kirkland, QC H9H 4M7
Founded in 1982
Merck Canada Inc.'s KEYTRUDA (pembrolizumab) Receives Conditional Approval in Canada for the Treatment of Advanced Melanoma
Jun 8 15
Merck Canada Inc. announced that KEYTRUDATM (pembrolizumab) was authorized for sale with conditions by Health Canada on May 19, 2015. KEYTRUDA is a humanized monoclonal antibody that works by increasing the ability of the body's immune system to fight advanced melanoma, the most serious form of skin cancer1. It is the first of a new class of therapies called anti-PD-1s approved in Canada. Among the different types of skin cancer, melanoma has the metastatic potential2. KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor3. The product has been approved in Canada under the Notice of Compliance with Conditions (NOC/c) policy on the basis of promising evidence of clinical effectiveness and pending the results ofÂ trials to verify its anticipated benefit.
Merck Canada Inc Appoints Chirfi Guindo to President and Managing Director
Oct 13 14
Merck Canada Inc. announced the appointment of Chirfi Guindo to President and Managing Director.